Current status and perspective of antiangiogenic therapy for cancer: Urinary cancer

International Journal of Clinical Oncology

Volumn 11, Issue 2, 2006, Pages 90-107

  Kanda, Shigeru ^a,b   Miyata, Yasuyoshi ^a   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Angiogenesis; FGF; p53; Thymidine phosphorylase; Urological cancer; VEGF

Indexed keywords

2 METHOXYESTRADIOL; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIESTROGEN; AXITINIB; BCG VACCINE; CANDESARTAN; CANERTINIB; CELECOXIB; CETUXIMAB; COPOLYMER; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IM 862; INTERLEUKIN 12; INTERLEUKIN 2; LENALIDOMIDE; MEDROXYPROGESTERONE ACETATE; MITOMYCIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; SEMAXANIB; SORAFENIB; SUNITINIB; SURAMIN; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ABSENCE OF SIDE EFFECTS; ACNE; AMEBIASIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ASTHENIA; ATAXIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CARDIOTOXICITY; CELL PROLIFERATION; CEREBELLUM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CYTOSTASIS; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FATIGUE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC TRANSCRIPTION; GRANULOCYTOPENIA; HEMOPTYSIS; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY DYSFUNCTION; LETHARGY; LIVER DISEASE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHOCYTOPENIA; METASTASIS; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; NYSTAGMUS; PAIN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; TASTE DISORDER; THROMBOEMBOLISM; TRYPANOSOMIASIS; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; URINARY TRACT CANCER;

ANGIOGENESIS INHIBITORS; HUMANS; LYMPHANGIOGENESIS; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; UROGENITAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645842234     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0565-6     Document Type: Review

References (268)

1. J Folkman 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 4 6
2. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature (Lond) 407 249 257
3. A Bikfalvi R Bicknell 2002 Recent advances in angiogenesis, anti-angiogenesis and vascular targeting Trends Pharmacol Sci 23 576 582
4. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027
5. JH Mydlo WD Heston WR Fair 1988 Characterization of a heparin-binding growth factor from adenocarcinoma of the kidney J Urol 140 1575 1579
6. S Kanda H Hisamatsu T Igawa 1993 Peritubular endothelial cell proliferation in mice during compensatory renal growth after unilateral nephrectomy Am J Physiol 265 F712 716
7. J Eguchi K Nomata S Kanda 1992 Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma Biochem Biophys Res Commun 183 937 944
8. N Emoto O Isozaki E Ohmura 1994 Basic fibroblast growth factor (FGF-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growth J Urol 152 1626 1631
9. LF Brown B Berse RW Jackman 1993 Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas Am J Pathol 143 1255 1262
10. A Takahashi H Sasaki SJ Kim 1994 Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis Cancer Res 54 4233 4237
11. N Ferrara 2004 Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 581 611
12. BA Keyt LT Berleau HV Nguyen 1996 The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency J Biol Chem 271 7788 7795
13. KA Houck DW Leung AM Rowland 1992 Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms J Biol Chem 267 26031 26037
14. JE Park GA Keller N Ferrara 1993 The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1317 1326
15. J Plouet F Moro S Bertagnolli 1997 Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect J Biol Chem 272 13390 13396
16. 165 in renal cell carcinoma Anticancer Res 19 1563 1565
17. M Tomisawa T Tokunaga Y Oshika 1999 Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma Eur J Cancer 35 133 137
18. JR Gnarra K Tory Y Weng 1994 Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 85 90
19. T Shuin K Kondo S Torigoe 1994 Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 54 2852 2855
20. KL Covello MC Simon 2004 HIFs, hypoxia, and vascular development Curr Top Dev Biol 62 37 54
21. CJ Schofield PJ Ratcliffe 2005 Signalling hypoxia by HIF hydroxylases Biochem Biophys Res Commun 338 617 626
22. T Shuin I Yamazaki K Tamura 2004 Recent advances in ideas on the molecular pathology and clinical aspects of von Hippel-Lindau disease Int J Clin Oncol 9 283 287
23. J Brieger EJ Weidt P Schirmacher 1999 Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors J Mol Med 77 505 510
24. H Okuda K Saitoh S Hirai 2001 The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J Biol Chem 276 43611 43617
25. A Danilkovitch-Miagkova B Zbar 2002 Dysregulation of Met receptor tyrosine kinase activity in invasive tumors J Clin Invest 109 863 867
26. PG Natali M Prat MR Nicotra 1996 Overexpression of the met/HGF receptor in renal cell carcinomas Int J Cancer 69 212 217
27. T Nakamura S Kanda K Yamamoto 2001 Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation Oncogene 20 7610 7623
28. YW Zhang Y Su OV Volpert 2003 Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation Proc Natl Acad Sci U S A 100 12718 12723
29. Y Miyata S Ashida T Nakamura 2003 Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo Biochem Biophys Res Commun 302 892 897
30. C Kuhnen T Muehlberger M Honsel 2003 Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density J Cancer Res Clin Oncol 129 415 422
31. D Strohmeyer F Strauss C Rossing 2004 Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma Anticancer Res 24 1797 1804
32. S Corso PM Comoglio S Giordano 2005 Cancer therapy: can the challenge be MET? Trends Mol Med 11 284 292
33. SC Jacobs RK Lawson 1980 Mitogenic factor in human prostate extracts Urology 16 488 491
34. MT Story F Esch S Shimasaki 1987 Amino-terminal sequence of a large form of basic fibroblast growth factor isolated from human benign prostatic hyperplastic tissue Biochem Biophys Res Commun 142 702 709
35. JW Crabb LG Armes SA Carr 1986 Complete primary structure of prostatropin, a prostate epithelial cell growth factor Biochemistry 25 4988 4993
36. DM Ornitz N Itoh 2001 Fibroblast growth factors Genome Biol 2 3005.1 3005.12
37. P Klint L Claesson-Welsh 1999 Signal transduction by fibroblast growth factor receptors Front Biosci 4 D165 D177
38. VP Eswarakumar I Lax J Schlessinger 2005 Cellular signaling by fibroblast growth factor receptors Cytokine Growth Factor Rev 16 139 149
39. HD Beer L Vindevoghel MJ Gait 2000 Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain J Biol Chem 275 16091 16097
40. T Nakamura Y Mochizuki H Kanetake 2001 Signals via FGF receptor 2 regulate migration of endothelial cells Biochem Biophys Res Commun 289 801 806
41. D Giri F Ropiquet M Ittmann 1999 Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer Clin Cancer Res 5 1063 1071
42. B Kwabi-Addo F Ropiquet D Giri 2001 Alternative splicing of fibroblast growth factor receptors in human prostate cancer Prostate 46 163 172
43. J Wang DW Stockton M Ittmann 2004 The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression Clin Cancer Res 10 6169 6178
44. F Ropiquet D Giri B Kwabi-Addo 2000 Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer Cancer Res 60 4245 4250
45. N Polnaszek B Kwabi-Addo J Wang M Ittmann 2004 FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia Prostate 2004 60 18 24
46. TJ Dorkin MC Robinson C Marsh 1999 a-FGF immunoreactivity in prostate cancer and its co-localization with b-FGF and FGF-8 J Pathol 189 564 569
47. HY Leung C Dickson CN Robson 1996 Over-expression of fibroblast growth factor-8 in human prostate cancer Oncogene 12 1833 1835
48. TJ Dorkin MC Robinson C Marsh 1999 FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease Oncogene 18 2755 2761
49. T Sugamoto N Tanji K Sato 2001 The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization Anticancer Res 21 77 88
50. IB Joseph JT Isaacs 1997 Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers Cancer Res 57 1054 1057
51. M Colombel S Filleur P Fournier 2005 Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate Cancer Res 65 300 308
52. JA Doll FK Reiher SE Crawford 2001 Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate Prostate 49 293 305
53. SJ Shih MA Dall'Era JR Westphal 2003 Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue Prostate Cancer Prostatic Dis 6 131 137
54. SJ Foley DM Bailey 2000 Microvessel density in prostatic hyperplasia BJU Int 85 70 73
55. BH Bochner RJ Cote N Weidner 1995 Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis J Natl Cancer Inst 87 1603 1612
56. EA Philp TJ Stephenson MW Reed 1996 Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder Br J Urol 77 352 357
57. CP Dinney RC Babkowski M Antelo 1998 Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder J Urol 160 1285 1290
58. O Sagol K Yorukoglu B Sis 2001 Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder? Urology 57 895 899
59. T O'Brien D Cranston S Fuggle 1995 Different angiogenic pathways characterize superficial and invasive bladder cancer Cancer Res 55 510 513
60. NH Chow HS Liu SH Chan 1999 Expression of vascular endothelial growth factor in primary superficial bladder cancer Anticancer Res 19 4593 4597
61. C Prives PA Hall 1999 The p53 pathway J Pathol 187 112 126
62. KM Dameron OV Volpert MA Tainsky 1994 Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science 265 1582 1584
63. H Nishimori T Shiratsuchi T Urano 1997 A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis Oncogene 15 2145 2150
64. ZA Sherif S Nakai KF Pirollo 2001 Downmodulation of bFGF-binding protein expression following restoration of p53 function Cancer Gene Ther 8 771 782
65. CJ Powers SW McLeskey A Wellstein 2000 Fibroblast growth factors, their receptors and signaling Endocr Relat Cancer 7 165 197
66. R Ravi B Mookerjee ZM Bhujwalla 2000 Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes Dev 14 34 44
67. L Zhang D Yu M Hu 2000 Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression Cancer Res 60 3655 3661
68. N Malats A Bustos CM Nascimento 2005 P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 678 686
69. GD Grossfeld DA Ginsberg JP Stein 1997 Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression J Natl Cancer Inst 89 219 227
70. VE Theodoropoulos AC Lazaris F Sofras 2004 Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer Eur Urol 46 200 208
71. MS Greenblatt WP Bennett M Hollstein 1994 Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 4855 4878
72. UM Moll N Slade 2004 p63 and p73: roles in development and tumor formation Mol Cancer Res 2 371 386
73. S Akiyama T Furukawa T Sumizawa 2004 The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression Cancer Sci 95 851 857
74. F Ishikawa K Miyazono U Hellman 1989 Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor Nature (Lond) 338 557 562
75. NS Brown A Jones C Fujiyama 2000 Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors Cancer Res 60 6298 6302
76. T O'Brien D Cranston S Fuggle R Bicknell AL Harris 1995 Different angiogenic pathways characterize superficial and invasive bladder cancer Cancer Res 55 510 513
77. TS O'Brien SB Fox AJ Dickinson 1996 Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers Cancer Res 56 4799 4804
78. J Arima Y Imazono Y Takebayashi 2000 Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder Cancer (Phila) 88 1131 1138
79. T Tammela TV Petrova K Alitalo 2005 Molecular lymphangiogenesis: new players Trends Cell Biol 15 434 441
80. MJ Cross J Dixelius T Matsumoto 2003 VEGF-receptor signal transduction Trends Biochem Sci 28 488 494
81. T Makinen T Veikkola S Mustjoki 2001 Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3 EMBO J 20 4762 4773
82. Y Cao P Linden J Farnebo 1998 Vascular endothelial growth factor C induces angiogenesis in vivo Proc Natl Acad Sci U S A 95 14389 14394
83. L Marconcini S Marchio L Morbidelli 1999 c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro Proc Natl Acad Sci U S A 96 9671 9676
84. NL Ward DJ Dumont 2002 The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development Semin Cell Dev Biol 13 19 27
85. NW Gale G Thurston SF Hackett 2002 Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1 Dev Cell 3 411 423
86. Y Cao 2005 Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis Nat Rev Cancer 5 735 743
87. SP Gunningham MJ Currie C Han 2001 Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia Cancer Res 61 3206 3211
88. N Tsuchiya K Sato T Akao 2001 Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma Tohoku J Exp Med 195 101 113
89. T Tsurusaki S Kanda H Sakai 1999 Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis Br J Cancer 80 309 313
90. ME Stearns M Wang Y Hu 2004 Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis Lab Invest 84 785 795
91. J Li E Wang F Rinaldo 2005 Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway Oncogene 24 5510 5520
92. K Suzuki T Morita A Tokue 2005 Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder Int J Urol 12 152 158
93. Y Miyata S Kanda K Ohba 2006 Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implication and regulation by vascular endothelial growth factors-A, -C, and -D Clin Cancer Res 12 800 806
94. AJ Lind P Wikstrom T Granfors 2005 Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer Prostate 62 394 399
95. N Oka Y Yamamoto M Takahashi 2005 Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer BJU Int 95 660 663
96. G Concolino F Di Silverio A Marocchi 1979 Renal cancer steroid receptors: biochemical basis for endocrine therapy Eur Urol 5 90 93
97. J Gross RG Azizkhan C Biswas 1981 Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone Proc Natl Acad Sci U S A 78 1176 1180
98. A Gagliardi DC Collins 1993 Inhibition of angiogenesis by antiestrogens Cancer Res 53 533 535
99. J Atzpodien H Kirchner HJ Illiger 2001 IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial Br J Cancer 85 1130 1136
100. DJ Lindner 2002 Interferons as antiangiogenic agents Curr Oncol Rep 4 510 514
101. CP Dinney DR Bielenberg P Perrotte 1998 Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration Cancer Res 58 808 814
102. Z von Marschall A Scholz T Cramer 2003 Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis J Natl Cancer Inst 95 437 448
103. AL Angiolillo C Sgadari DD Taub 1995 Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo J Exp Med 182 155 162
104. R Raffaella D Gioia M De Andrea 2004 The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells Exp Cell Res 293 331 345
105. EL Schwartz E Wan FS Wang 1998 Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells Cancer Res 58 1551 1557
106. F Cozzolino M Torcia M Lucibello 1993 Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth J Clin Invest 91 2504 2512
107. C Coppin F Porzsolt A Awa 2004 Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 1 CD001425
108. J Atzpodien H Kirchner U Jonas 2004 Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 22 1188 1194
109. S Négrier B Escudier C Lasset 1998 Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie N Engl J Med 338 1272 1278
110. S Négrier A Caty T Lesimple 2000 Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil: Groupe Francais d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer J Clin Oncol 18 4009 4015
111. S Négrier 2004 Better survival with interleukin-2-based regimens? Possibly only in highly selected patients J Clin Oncol 22 1174 1176
112. EE Voest BM Kenyon MS O'Reilly 1995 Inhibition of angiogenesis in vivo by interleukin 12 J Natl Cancer Inst 87 581 586
113. C Sgadari AL Angiolillo G Tosato 1996 Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 Blood 87 3877 3882
114. RJ Motzer A Rakhit JA Thompson 2001 Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma J Interferon Cytokine Res 21 257 263
115. JA Gollob KG Veenstra RA Parker 2003 Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma J Clin Oncol 21 2564 2573
116. G Alatrash TE Hutson L Molto 2004 Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma J Clin Oncol 22 2891 2900
117. T Kondo F Ito H Nakazawa 2004 High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma J Urol 171 2171 2175
118. CA Stein 1993 Suramin: a novel antineoplastic agent with multiple potential mechanisms of action Cancer Res 53 2239 2248
119. RJ Motzer DM Nanus P O'Moore 1992 Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression Cancer Res 52 5775 5779
120. R Dreicer DC Smith RD Williams 1999 Phase II trial of suramin in patients with metastatic renal cell carcinoma Invest New Drugs 17 183 186
121. LE Schroder D Lew RC Flanigan 2001 Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study Urol Oncol 6 145 148
122. C Myers M Cooper C Stein 1992 Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10 881 889
123. PN Lara Jr P Twardowski DI Quinn 2004 Angiogenesis-targeted therapies in prostate cancer Clin Prostate Cancer 3 165 173
124. EJ Small A McMillan M Meyer 2001 Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival J Clin Oncol 19 5 1304 1311
125. JM Garcia-Schurmann H Schulze G Haupt 1999 Suramin treatment in hormone- and chemotherapy-refractory prostate cancer Urology 53 535 541
126. A Falcone A Antonuzzo R Danesi 1999 Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma Cancer (Phila) 86 470 476
127. EJ Small M Meyer ME Marshall 2000 Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J Clin Oncol 18 1440 1450
128. E Calvo J Cortes J Rodriguez 2001 Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma: a multicenter Phase II study Cancer (Phila) 92 2435 2443
129. EJ Small S Halabi MJ Ratain 2002 Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480 J Clin Oncol 20 3369 3375
130. NJ Vogelzang T Karrison WM Stadler 2004 A Phase II trial of suramin monthly ×3 for hormone-refractory prostate carcinoma Cancer (Phila) 100 65 71
131. EM Uchio WM Linehan WD Figg 2003 A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder J Urol 169 357 360
132. JJ Ord E Streeter A Jones 2005 Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma Br J Cancer 92 2140 2147
133. D Ingber T Fujita S Kishimoto 1990 Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature (Lond) 348 555 557
134. A Hori S Ikeyama K Sudo 1994 Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells Biochem Biophys Res Commun 204 1067 1073
135. J Abe W Zhou N Takuwa 1994 A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells Cancer Res 54 3407 3412
136. N Sin L Meng MQ Wang 1997 The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proc Natl Acad Sci U S A 94 6099 6103
137. M Yamaoka T Yamamoto S Ikeyama 1993 Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines Cancer Res 53 5233 5236
138. T Yanase M Tamura K Fujita 1993 Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo Cancer Res 53 2566 2570
139. T Morita N Shinohara A Tokue 1994 Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma Br J Urol 74 416 421
140. HJ Bernsen PF Rijken H Peters 1998 The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice J Neuro-oncol 38 51 57
141. C Morales M Zurita J Vaquero 2002 Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor J Neuro-oncol 58 131 136
142. J Huang JS Frischer T New 2004 TNP-470 promotes initial vascular sprouting in xenograft tumors Mol Cancer Ther 3 335 343
143. WM Stadler T Kuzel C Shapiro 1999 Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma J Clin Oncol 17 2541 2545
144. CJ Logothetis KK Wu LD Finn 2001 Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin Cancer Res 7 1198 1203
145. R Satchi-Fainaro M Puder JW Davies 2004 Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 Nat Med 10 255 261
146. AL Moreira EP Sampaio A Zmuidzinas 1993 Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1675 1680
147. JA Keifer DC Guttridge BP Ashburner 2001 Inhibition of NF-kappa B activity by thalidomide through suppression of I-kappa-B kinase activity J Biol Chem 276 22382 22387
148. J Fujita JR Mestre JB Zeldis 2001 Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 Clin Cancer Res 7 3349 3355
149. J Stebbing C Benson T Eisen 2001 The treatment of advanced renal cell cancer with high-dose oral thalidomide Br J Cancer 85 953 958
150. RJ Motzer W Berg M Ginsberg 2002 Phase II trial of thalidomide for patients with advanced renal cell carcinoma J Clin Oncol 20 302 306
151. B Escudier N Lassau D Couanet 2002 Phase II trial of thalidomide in renal-cell carcinoma Ann Oncol 13 1029 1035
152. DD Daliani CN Papandreou PF Thall 2002 A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma Cancer (Phila) 95 758 765
153. AA Desai NJ Vogelzang BI Rini 2002 A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma Cancer (Phila) 95 1629 1636
154. PD Nathan ME Gore TG Eisen 2002 Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma J Clin Oncol 20 1429 1430
155. Hernberg M, Virkkunen P, Bono P, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770-3776
156. SC Dixon EA Kruger KS Bauer 1999 Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells Cancer Chemother Pharmacol 43 suppl S78 S84
157. WD Figg W Dahut P Duray 2001 A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 1888 1893
158. MJ Drake W Robson P Mehta 2003 An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer Br J Cancer 88 822 827
159. WD Figg P Arlen J Gulley 2001 A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer Semin Oncol 28 4 suppl 15 62 66
160. MK Horne III WD Figg P Arlen 2003 Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer Pharmacotherapy 23 315 318
161. WL Dahut JL Gulley PM Arlen 2004 Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2532 2539
162. DZ Chang W Lomazow C Joy Somberg 2004 Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines Hematology 9 207 215
163. EJ Small DM Reese B Um 1999 Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor Clin Cancer Res 5 1738 1744
164. TD Eubank R Roberts M Galloway 2004 GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice Immunity 21 831 842
165. R Dreicer EA Klein P Elson 2005 Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer Urol Oncol 23 82 86
166. JB Bartlett A Tozer D Stirling 2005 Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Br J Cancer 93 613 619
167. P Falardeau P Champagne P Poyet 2001 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials Semin Oncol 28 620 625
168. G Batist F Patenaude P Champagne 2002 Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels Ann Oncol 13 1259 1263
169. RM Bukowski 2003 AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma Expert Opin Invest Drugs 12 1403 1411
170. LC Armstrong P Bornstein 2003 Thrombospondins 1 and 2 function as inhibitors of angiogenesis Matrix Biol 22 63 71
171. B Sid H Sartelet G Bellon 2004 Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth Crit Rev Oncol Hematol 49 245 258
172. S Kanda T Shono B Tomasini-Johansson 1999 Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis Exp Cell Res 252 262 272
173. Y Miyata S Koga K Takehara 2003 Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis Clin Cancer Res 9 1734 1740
174. J Lawler M Detmar 2004 Tumor progression: the effects of thrombospondin-1 and -2 Int J Biochem Cell Biol 36 1038 1045
175. F Haviv MF Bradley DM Kalvin 2005 Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities J Med Chem 48 2838 2846
176. R Hoekstra FY de Vos FA Eskens 2005 Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer J Clin Oncol 23 5188 5197
177. DL Simmons RM Botting T Hla 2004 Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol Rev 56 387 437
178. Y Miyata S Koga S Kanda 2003 Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival Clin Cancer Res 9 1741 1749
179. W Wang A Bergh JE Damber 2005 Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer Clin Cancer Res 11 3250 3256
180. T Shirahama J Arima S Akiba 2001 Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder Cancer (Phila) 92 188 193
181. RS Pruthi JE Derksen D Moore 2004 A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy BJU Int 93 275 278
182. BI Rini V Weinberg S Dunlap 2006 Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma Cancer (Phila) 106 566 575
183. E Okajima A Denda S Ozono 1998 Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine Cancer Res 58 3028 3031
184. NJ Mabjeesh D Escuin TM LaVallee 2003 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 3 363 375
185. C Sweeney G Liu C Yiannoutsos 2005 A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer Clin Cancer Res 11 6625 6633
186. EC Kohn R Alessandro J Spoonster 1995 Angiogenesis: role of calcium-mediated signal transduction Proc Natl Acad Sci U S A 92 1307 1311
187. EC Kohn WD Figg GA Sarosy 1997 Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations J Clin Oncol 15 1985 1993
188. KS Bauer WD Figg JM Hamilton 1999 A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer Clin Cancer Res 5 2324 2329
189. JP Dutcher L Leon J Manola 2005 Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy Cancer (Phila) 104 2392 2399
190. WM Stadler G Rosner E Small 2005 Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901 J Clin Oncol 23 3726 3732
191. G Patstone P Maher 1996 Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors J Biol Chem 271 3343 3346
192. CK Sen S Khanna M Venojarvi 2002 Copper-induced vascular endothelial growth factor expression and wound healing Am J Physiol Heart Circ Physiol 282 H1821 H1827
193. CK Sen VL Goodman GJ Brewer SD Merajver 2004 Copper deficiency as an anti-cancer strategy Endocr Relat Cancer 11 255 263
194. BG Redman P Esper Q Pan 2003 Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer Clin Cancer Res 9 1666 1672
195. A Tulpule BM Espina S Cabriales 2065 IM-862 nasal solution is an active antiangiogenic agent in the treatment of AIDS-related Kaposi's sarcoma Proc Am Soc Clin Oncol 18 535a (abstract)
196. A Ferrario KF von Tiehl N Rucker 2000 Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma Cancer Res 60 4066 4069
197. G Deplanque S Madhusudan PH Jones 2004 Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma Br J Cancer 91 1645 1650
198. F Deshayes C Nahmias 2005 Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16 293 299
199. H Uemura H Hasumi T Kawahara 2005 Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer Int J Clin Oncol 10 405 410
200. CJ Barnes R Kumar 2003 Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets Cancer Metastasis Rev 22 301 307
201. Dreux AC, Lamb DJ, Modjtahedi H, et al. (2006) The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis (in press)
202. H van Cruijsen G Giaccone K Hoekman 2005 Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies Int J Cancer 117 883 888
203. JH Mydlo J Michaeli C Cordon-Cardo 1989 Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue Cancer Res 49 3407 3411
204. GL Morris JG Dodd 1990 Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines J Urol 143 1272 1274
205. EM Messing 1990 Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma Cancer Res 50 2530 2537
206. G Stumm S Eberwein S Rostock-Wolf 1996 Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis Int J Cancer 69 17 22
207. S Signoretti R Montironi J Manola 2000 Her-2-neu expression and progression toward androgen independence in human prostate cancer J Natl Cancer Inst 92 1918 1925
208. S Kruger G Weitsch H Buttner 2002 HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications Int J Cancer 102 514 518
209. RJ Motzer R Amato M Todd 2003 Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Invest New Drugs 21 99 101
210. EK Rowinsky GH Schwartz JA Gollob 2004 Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer J Clin Oncol 22 3003 3015
211. NA Dawson C Guo R Zak 2004 A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma Clin Cancer Res 10 7812 7819
212. M Jermann RA Stahel M Salzberg 2006 A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma Cancer Chemother Pharmacol 57 533 539
213. CM Canil MJ Moore E Winquist 2005 Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 23 455 460
214. M Hidalgo LL Siu J Nemunaitis 2001 Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 3267 3279
215. M Beeram EK Rowinsky GR Weiss 2004 Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic and biological correlative study with FDG-PET imaging Proc Am Soc Clin Oncol 23 207 (abstract 3050)
216. E Calvo AW Tolcher LA Hammond 2004 Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study Clin Cancer Res 10 7112 7120
217. A Ziada A Barqawi LM Glode 2004 The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 332 337
218. LG Presta H Chen SJ O'Connor 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599
219. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335
220. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer N Engl J Med 349 427 434
221. DM Elaraj DE White SM Steinberg 2004 A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma J Immunother 27 259 264
222. JD Hainsworth JA Sosman DR Spigel 2005 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib J Clin Oncol 23 7889 7896
223. BI Rini S Halabi J Taylor 2004 Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma Clin Cancer Res 10 2584 2586
224. J Holash S Davis N Papadopoulos 2002 VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 11393 11398
225. C Cursiefen J Cao L Chen 2004 Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival Invest Ophthalmol Vis Sci 45 2666 2673
226. J Dupont L Schwartz J Koutcher 2004 Phase I and pharmacokinetic study of VEGF trap administerd subcutaneously to patients with advanced solid malignancies Proc Am Soc Clin Oncol 23 197 (abstract 3009)
227. BC Kuenen J Tabernero J Baselga 2003 Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma Clin Cancer Res 9 1648 1655
228. PN Lara Jr DI Quinn K Margolin 2003 SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition Clin Cancer Res 9 4772 4781
229. WM Stadler D Cao NJ Vogelzang 2004 A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer Clin Cancer Res 10 3365 3370
230. WM Stadler 2005 Targeted agents for the treatment of advanced renal cell carcinoma Cancer (Phila) 104 2323 2333
231. HS Rugo RS Herbst G Liu 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483
232. RJ Motzer M Dror Michaelson BG Redman 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24
233. SN Holden SG Eckhardt R Basser 2005 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 1391 1397
234. JF Lyons S Wilhelm B Hibner 2001 Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 219 225
235. SM Wilhelm C Carter L Tang 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109
236. D Strumberg H Richly RA Hilger 2005 Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965 972
237. A Awada A Hendlisz T Gil 2005 Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 1855 1861
238. M Moore HW Hirte L Siu 2005 Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Ann Oncol 16 1688 1694
239. P Traxler PR Allegrini R Brandt 2004 AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 4931 4941
240. RC Young 1998 Metastatic renal-cell carcinoma: what causes occasional drastic regression? N Engl J Med 338 1305 1306
241. ME Gleave M Elhilali Y Fradet 1998 Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group N Engl J Med 338 1265 1271
242. RT Oliver AB Nethersell JM Bottomley 1989 Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma Br J Urol 63 128 131
243. C Betsholtz A Johnsson CH Heldin 1986 Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin Proc Natl Acad Sci U S A 83 6440 6444
244. RJ Coffey Jr EB Leof GD Shipley 1987 Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells J Cell Physiol 132 143 148
245. SR Coughlin PJ Barr LS Cousens 1988 Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo J Biol Chem 263 988 993
246. N Vaisman D Gospodarowicz G Neufeld 1990 Characterization of the receptors for vascular endothelial growth factor J Biol Chem 265 19461 19466
247. JC Adams RA Furlong FM Watt 1991 Production of scatter factor by ndk, a strain of epithelial cells, and inhibition of scatter factor activity by suramin J Cell Sci 98 385 394
248. E Pesenti F Sola N Mongelli 1992 Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity Br J Cancer 66 367 372
249. BC Kuenen G Giaccone R Ruijter 2005 Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies Clin Cancer Res 11 6240 6246
250. JT Roberts 2005 Chemotherapy for metastatic bladder cancer Clin Oncol (R Coll Radiol) 17 514 523
251. J Logue CA McBain 2005 Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery Clin Oncol (R Coll Radiol) 17 508 513
252. KO Leonhardt RR Landes 1963 Oxygen tension of the urine and renal structures. Preliminary report of clinical findings N Engl J Med 269 115 121
253. M Hockel P Vaupel 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 266 276
254. KO Leonhardt RR Landes 1965 Urinary oxygen pressure in renal parenchymal and vascular disease. Effects of breathing oxygen JAMA 194 345 350
255. T Boehm J Folkman T Browder 1997 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature (Lond) 390 404 407
256. O Casanovas DJ Hicklin G Bergers 2005 Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 299 309
257. K Hida Y Hida DN Amin 2004 Tumor-associated endothelial cells with cytogenetic abnormalities Cancer Res 64 8249 8255
258. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature (Lond) 438 932 936
259. G Bergers S Song N Meyer-Morse 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 1287 1295
260. C Suri PF Jones S Patan 1996 Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1171 1180
261. PC Maisonpierre C Suri PF Jones 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 55 60
262. I Kim JH Kim SO Moon 2000 Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway Oncogene 19 4549 4552
263. K Teichert-Kuliszewska PC Maisonpierre N Jones 2001 Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2 Cardiovasc Res 49 659 670
264. Y Mochizuki T Nakamura H Kanetake 2002 Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn J Cell Sci 115 175 183
265. J Oliner H Min J Leal 2004 Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 507 516
266. L Holmgren MS O'Reilly J Folkman 1995 Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 149 153
267. KD Miller CJ Sweeney GW Sledge Jr 2001 Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 1195 1206
268. M Garcia-Barros F Paris C Cordon-Cardo 2003 Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 300 1155 1159